

## BIBLIOGRAFÍA

1. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. *Acta Diabetol* 2005;42:S17-S25.
2. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes (Technical Review). *Diabetes Care* 2002;25:134-47.
3. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al.; the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach. *American Journal of Kidney Diseases* 2000;36:646-61.
4. Vijan S, Hayward R. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. *Ann Intern Med* 2003;138:593-602.
5. Campbell NRC, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, et al. Hypertension in diabetes: A call to action. *Can J Cardiol* 2009;25:299-302.
6. The hypertension in diabetes study group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. *J Hypertens* 1993;11:309-17.
7. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. *Am J Med* 2001;111:633-42.
8. McFarlane S, Castro J, Kirpichnikov D, Sowers J. Hipertensión en la diabetes mellitus. En: Khan (ed.). *Joslin's Diabetes Mellitus* 14.ª edición. Madrid: Adis Communications; 2005. p. 969-974.
9. Eguchi K, Pickering TG, Hoshida S, Ishikawa J, Ishikawa S, Schwartz JE, et al. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. *Am J Hypertens* 2008;21:443-50.
10. Parati G, Bilò G. Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes? *Diabetes Care* 2009;32:S298-S304.
11. Gerstein H, Mann J, Zinman B, Dinneen S, Hoogwerf B, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001;286:421-6.
12. Banegas J, Jovell A, Abarca B, Aguilar M, Aguilera L, Aranda P. Hipertensión arterial y política de salud en España. *Med Clin* 2009;132:222-9.
13. Miguel García F, García Ortiz A, Montero Alonso M. Tratamiento de la hipertensión arterial en los diabéticos: una revisión crítica. *SEMERGEN* 2007;33:241-9.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens* 2009;27:2121-58.
15. Soriano Cabrera S. Definición y clasificación de los estadios de la enfermedad renal crónica. Prevalencia. Claves para el diagnóstico precoz. Factores de riesgo de enfermedad renal crónica. Guías SEN. Riñón y enfermedad cardiovascular. *Nefrología* 2004;24:27-34.
16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *NEJM* 2004;351:1296-305.
17. Hoogwerf B. Renin-angiotensin system blockade and cardiovascular and renal protection. *Am J Cardiol* 2010;105:30A-35A.
18. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *NEJM* 2008;358:1547-59.
19. Naik AD, Kallen MA, Walder A, Street RL Jr. Improving hypertension control in diabetes mellitus: The effects of collaborative and proactive health communication. *Circulation* 2008;117:1361-8.
20. Sampanis C, Zamboulis C. Arterial hypertension in diabetes mellitus: from theory to clinical practice. *Hippokratia* 2008;12:74-80.
21. Sikon A, Bronson D. Shared medical appointments: challenges and opportunities. *Ann Intern Med* 2010;152:745-6.